ReviewGlobal challenges (Hoboken, NJ)2021
Droplet Microfluidics for Tumor Drug-Related Studies and Programmable Artificial Cells.
Review in Global challenges (Hoboken, NJ), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Mechanical Signaling: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2025Review
- 2D versus 3D tumor-on-chip models to study the impact of tumor organization on metabolic patterns in vitro.Scientific reports · 2025Article
- On-demand droplet formation at a T-junction: modelling and validation.Microsystems & nanoengineering · 2025Article
- Microfluidic Technologies in Advancing Cancer Research.Micromachines · 2024Review
- A Novel Acoustic Modulation of Oscillating Thin Elastic Membrane for Enhanced Streaming in Microfluidics and Nanoscale Liposome Production.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Review
- Roadmap on multifunctional materials for drug delivery.JPhys materials · 2024Review
- Engineering Heterogeneous Tumor Models for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Lipid-Based Nanotechnology: Liposome.Pharmaceutics · 2023Review
- Microfluidics for nano-drug delivery systems: From fundamentals to industrialization.Acta pharmaceutica Sinica. B · 2023Review
- Droplet-Based Microfluidics: Applications in Pharmaceuticals.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Chitosan and Pectin Hydrogels for Tissue Engineering and In Vitro Modeling.Gels (Basel, Switzerland) · 2023Review
- Microfluidic Formulation of Topological Hydrogels for Microtissue Engineering.Chemical reviews · 2022Review
- Droplet Microfluidics-Based Fabrication of Monodisperse Poly(ethylene glycol)-Fibrinogen Breast Cancer Microspheres for Automated Drug Screening Applications.ACS biomaterials science & engineering · 2022Article
- Review
- USE OF ARTIFICIAL CELLS AS DRUG CARRIERS.Materials chemistry frontiers · 2021Article
- Droplet Microfluidics for Tumor Drug-Related Studies and Programmable Artificial Cells.Global challenges (Hoboken, NJ) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticancer drug development is a crucial step toward cancer treatment, that requires realistic predictions of malignant tissue development and sophisticated drug delivery. Tumors often acquire drug resistance and drug efficacy, hence cannot be accurately predicted in 2D tumor cell cultures. On the other hand, 3D cultures, including multicellular tumor spheroids (MCTSs), mimic the in vivo cellular arrangement and provide robust platforms for drug testing when grown in hydrogels with characteristics similar to the living body. Microparticles and liposomes are considered smart drug delivery vehicles, are able to target cancerous tissue, and can release entrapped drugs on demand. Microfluidics serve as a high-throughput tool for reproducible, flexible, and automated production of droplet-based microscale constructs, tailored to the desired final application. In this review, it is described how natural hydrogels in combination with droplet microfluidics can generate MCTSs, and the use of microfluidics to produce tumor targeting microparticles and liposomes. One of the highlights of the review documents the use of the bottom-up construction methodologies of synthetic biology for the formation of artificial cellular assemblies, which may additionally incorporate both target cancer cells and prospective drug candidates, as an integrated "droplet incubator" drug assay platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.